IL321414A - Vaccines against respiratory diseases - Google Patents
Vaccines against respiratory diseasesInfo
- Publication number
- IL321414A IL321414A IL321414A IL32141425A IL321414A IL 321414 A IL321414 A IL 321414A IL 321414 A IL321414 A IL 321414A IL 32141425 A IL32141425 A IL 32141425A IL 321414 A IL321414 A IL 321414A
- Authority
- IL
- Israel
- Prior art keywords
- respiratory diseases
- vaccines against
- against respiratory
- vaccines
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363480504P | 2023-01-18 | 2023-01-18 | |
| US202363586506P | 2023-09-29 | 2023-09-29 | |
| US202363610006P | 2023-12-14 | 2023-12-14 | |
| US202363611808P | 2023-12-19 | 2023-12-19 | |
| PCT/IB2024/050404 WO2024154048A1 (en) | 2023-01-18 | 2024-01-16 | Vaccines against respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321414A true IL321414A (en) | 2025-08-01 |
Family
ID=89661946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321414A IL321414A (en) | 2023-01-18 | 2025-06-10 | Vaccines against respiratory diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240252614A1 (en) |
| EP (1) | EP4651889A1 (en) |
| JP (1) | JP2026504862A (en) |
| KR (1) | KR20250122511A (en) |
| CN (1) | CN120548194A (en) |
| AU (1) | AU2024209772A1 (en) |
| CO (1) | CO2025009576A2 (en) |
| IL (1) | IL321414A (en) |
| MX (1) | MX2025008379A (en) |
| PE (1) | PE20252308A1 (en) |
| TW (1) | TW202436325A (en) |
| WO (1) | WO2024154048A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025119162A1 (en) * | 2023-12-04 | 2025-06-12 | 深圳深信生物科技有限公司 | Metapneumovirus (mpv) vaccine |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| FR2726003B1 (en) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| SE0202110D0 (en) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| SE0301998D0 (en) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| JP5639338B2 (en) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | Liposome production system and production method |
| US8563002B2 (en) | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| PL2445526T3 (en) | 2009-06-24 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
| EP4183412B1 (en) | 2009-07-15 | 2024-08-14 | GlaxoSmithKline Biologicals SA | Rsv f protein compositions and methods for making same |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| EP4421177A3 (en) | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| PT2988780T (en) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Stabilized soluble prefusion rsv f polypeptides |
| CN105408348B (en) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | Stabilized soluble prefusion RSV F polypeptide |
| WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| US10420834B2 (en) | 2014-12-24 | 2019-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus F proteins and their use |
| CN107847580B (en) | 2015-07-07 | 2022-08-12 | 扬森疫苗与预防公司 | Vaccines against RSV |
| AU2016289496B2 (en) | 2015-07-07 | 2021-02-04 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| RU2723039C2 (en) | 2015-12-23 | 2020-06-08 | Пфайзер Инк. | Protein f rsv mutants |
| AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| WO2018081289A2 (en) | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion piv f immunogens and their use |
| WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| KR20220010478A (en) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | Subunit vaccines for the treatment or prevention of respiratory tract infections |
| US12679870B2 (en) | 2020-04-29 | 2026-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant human metapneumovirus F proteins and their use |
| EP4171627A1 (en) | 2020-06-29 | 2023-05-03 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
| IL320367A (en) | 2020-10-09 | 2025-06-01 | Univ Texas | Pre-stabilized HMPV F proteins |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| KR20230167017A (en) | 2021-04-09 | 2023-12-07 | 발네바 에스이 | Human metapneumovirus vaccine |
| AR127808A1 (en) | 2021-11-30 | 2024-02-28 | Sanofi Pasteur Inc | VACCINES AGAINST THE HUMAN METAPNEUMOVIRUS |
| JP2024544054A (en) | 2021-11-30 | 2024-11-27 | サノフィ パスツール インコーポレイテッド | Viral vector-based vaccine for human metapneumovirus |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| AU2023269241A1 (en) | 2022-05-12 | 2024-11-21 | Msd International Business Gmbh | Stabilized pre-fusion hmpv fusion proteins |
-
2024
- 2024-01-16 CN CN202480008127.XA patent/CN120548194A/en active Pending
- 2024-01-16 TW TW113101740A patent/TW202436325A/en unknown
- 2024-01-16 US US18/413,734 patent/US20240252614A1/en active Pending
- 2024-01-16 EP EP24701290.9A patent/EP4651889A1/en active Pending
- 2024-01-16 KR KR1020257023598A patent/KR20250122511A/en active Pending
- 2024-01-16 AU AU2024209772A patent/AU2024209772A1/en active Pending
- 2024-01-16 PE PE2025001483A patent/PE20252308A1/en unknown
- 2024-01-16 WO PCT/IB2024/050404 patent/WO2024154048A1/en not_active Ceased
- 2024-01-16 JP JP2025541019A patent/JP2026504862A/en active Pending
-
2025
- 2025-06-10 IL IL321414A patent/IL321414A/en unknown
- 2025-07-15 CO CONC2025/0009576A patent/CO2025009576A2/en unknown
- 2025-07-17 MX MX2025008379A patent/MX2025008379A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250122511A (en) | 2025-08-13 |
| EP4651889A1 (en) | 2025-11-26 |
| US20240252614A1 (en) | 2024-08-01 |
| JP2026504862A (en) | 2026-02-10 |
| MX2025008379A (en) | 2025-08-01 |
| TW202436325A (en) | 2024-09-16 |
| PE20252308A1 (en) | 2025-09-22 |
| WO2024154048A1 (en) | 2024-07-25 |
| CO2025009576A2 (en) | 2025-08-08 |
| AU2024209772A1 (en) | 2025-06-26 |
| CN120548194A (en) | 2025-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202012021UA (en) | Interface assemblies for respiratory therapy | |
| EP3927405A4 (en) | ADJUSTABLE EXPIRATORY RELEASE IN RESPIRATORY THERAPY | |
| EP4034550A4 (en) | VACCINE THERAPY FOR RAN PROTEIN DISEASES | |
| CA204343S (en) | Inhaler | |
| CA193488S (en) | Inhaler | |
| EP4329849C0 (en) | Inhaler | |
| CA198068S (en) | Inhaler | |
| ZA201903426B (en) | Oral vaccine against ruminant respiratory disease comprising polyvinylpyrrolidone | |
| EP3755409A4 (en) | Oro-nasal patient interface for treating sleep disordered breathing | |
| EP4260722C0 (en) | Inhaler | |
| SG11202009955QA (en) | Headgear for use with a patient interface of a respiratory therapy system | |
| IL307268A (en) | Combination therapy for covid-19 vaccination | |
| GB202106160D0 (en) | Inhaler | |
| EP4410310A4 (en) | Prophylactic or therapeutic agent for respiratory diseases | |
| CA3280015A1 (en) | Vaccines against respiratory diseases | |
| GB202115132D0 (en) | Inhaler | |
| CA200217S (en) | Inhaler | |
| EP4744735A2 (en) | MEDICAL FACE MASK | |
| HUE065591T2 (en) | Medicament for treating infectious diseases | |
| GB202004337D0 (en) | Inhaler | |
| CA224059S (en) | Inhaler | |
| CA224060S (en) | Inhaler | |
| GB202315641D0 (en) | Breathing airways | |
| ZA202210371B (en) | Backpack ventilator for preventing respiratory infectious diseases | |
| CA209032S (en) | Inhaler |